Synapsin

Synapsin (also known as Intranasal Synapsin, RG3 + NAD+ compound) is a prominently researched experimental compound classified strictly within the Nootropic Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it compounded intranasal formulation (not a single peptide) combining Rg3 (ginsenoside), NAD+, and additional neuroprotective compounds. Rg3 modulates NMDA and GABA receptor activity, reduces neuroinflammation via NF-kB inhibition, and promotes BDNF expression. NAD+ component supports mitochondrial function and sirtuin activation. Intranasal delivery bypasses blood-brain barrier. Often used in TBI, post-COVID cognitive impairment, and neurodegenerative disease support protocols. with an established metabolic degradation profile, In preclinical investigative trials and independent academic studies, researchers utilizing Synapsin have documented significant, quantifiable biological outcomes, primarily focusing on cognitive enhancement, neuroprotection, mitochondrial function, synaptic plasticity. Typical research protocols investigate administering 100 to 200mcg via nasal pathways daily. However, it is critically important to understand that while Synapsin demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.